{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T04:58:40Z","timestamp":1764219520397,"version":"3.46.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000545","name":"the British Association of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bullous pemphigoid (BP) is a chronic, autoimmune, blistering disorder that predominantly affects older adults and is associated with significant morbidity and treatment challenges. The British Association of Dermatologists (BAD) clinical guideline for managing people with BP was published in 2012; a national clinical audit was undertaken in 2018. This 2024 reaudit evaluates changes in clinical practice, including diagnostic methods, treatment strategies and documentation standards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To reassess compliance with BAD audit standards, compare findings with the 2018 audit and identify trends in BP management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Over 9 weeks in 2024, BAD members submitted data for 450 cases of BP from 77 centres across the UK. Audit standards included documentation of comorbidities, osteoporosis risk management, patient satisfaction and systemic treatment monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The reaudit identified a shift in diagnostic practices, an increased proportion of severe baseline disease and continued gaps in \u00adosteoporosis risk documentation. The use of doxycycline as a primary treatment has increased significantly since 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings highlight both progress and persistent challenges in BP management. Improved documentation and greater adherence to osteoporosis management guidelines remain priorities for future practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/skinhd\/vzaf063","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T06:55:06Z","timestamp":1762671306000},"page":"419-425","source":"Crossref","is-referenced-by-count":0,"title":["National clinical reaudit on managing adults with bullous pemphigoid 2024 highlighting shifting clinical practices"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4599-9455","authenticated-orcid":false,"given":"Ravi","family":"Ramessur","sequence":"first","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King\u2019s College London , London ,","place":["UK"]},{"name":"Watford General Hospital, West Hertfordshire NHS Trust , Watford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayley","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe C","family":"Venables","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Norfolk and Norwich University Hospitals Foundation Trust , Norwich ,","place":["UK"]},{"name":"Norwich Medical School, University of East Anglia , Norwich ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Tumbeva","sequence":"additional","affiliation":[{"name":"Clinical Standards Unit, British Association of Dermatologists , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4070-0696","authenticated-orcid":false,"given":"M Firouz","family":"Mohd Mustapa","sequence":"additional","affiliation":[{"name":"Clinical Standards Unit, British Association of Dermatologists , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A R","family":"de Berker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Bristol Royal Infirmary , Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the British Association of Dermatologists\u2019 Clinical Standards Unit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A R","family":"de Berker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Ramessur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z C","family":"Venables","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Charman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Seddik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Tumbeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M F","family":"Mohd Mustapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2025112622313621200_vzaf063-B1","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"2025112622313621200_vzaf063-B2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025112622313621200_vzaf063-B3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2025112622313621200_vzaf063-B4","first-page":"595","article-title":"Comorbidities in patients with autoimmune bullous disorders: hospital-based registry study","volume":"12","author":"S\u00e1nchez-Garc\u00eda","year":"2022","journal-title":"Life (Basel)"},{"key":"2025112622313621200_vzaf063-B5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archderm.141.6.691","article-title":"Prediction of survival for patients with bullous pemphigoid: a prospective study","volume":"141","author":"Joly","year":"2005","journal-title":"Arch Dermatol"},{"key":"2025112622313621200_vzaf063-B6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.134.4.465","article-title":"High risk of death in elderly patients with extensive bullous pemphigoid","volume":"134","author":"Roujeau","year":"1998","journal-title":"Arch Dermatol"},{"key":"2025112622313621200_vzaf063-B7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000345625","article-title":"Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study","volume":"225","author":"Cort\u00e9s","year":"2012","journal-title":"Dermatology"},{"key":"2025112622313621200_vzaf063-B8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025112622313621200_vzaf063-B9","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"2025112622313621200_vzaf063-B10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ced.14086","article-title":"National audit on the management of bullous pemphigoid","volume":"45","author":"Smith","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2025112622313621200_vzaf063-B11","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.1038\/s41598-022-14950-z","article-title":"Bullous pemphigoid diagnosis: the role of routine formalin-fixed paraffin-embedded skin tissue immunochemistry","volume":"12","author":"Oh","year":"2022","journal-title":"Sci Rep"},{"author":"Statistics","key":"2025112622313621200_vzaf063-B12"},{"key":"2025112622313621200_vzaf063-B13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol"},{"key":"2025112622313621200_vzaf063-B14","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/s41467-018-06027-1","article-title":"The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature","volume":"9","author":"Inman","year":"2018","journal-title":"Nat Commun"},{"key":"2025112622313621200_vzaf063-B15","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/biomedicines10112844","article-title":"Bullous pemphygoid and novel therapeutic approaches","volume":"10","author":"D\u2019Agostino","year":"2022","journal-title":"Biomedicines"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/6\/419\/65236488\/vzaf063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/6\/419\/65236488\/vzaf063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T03:31:46Z","timestamp":1764214306000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/5\/6\/419\/8316061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,6]]},"published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzaf063","relation":{},"ISSN":["2690-442X"],"issn-type":[{"type":"electronic","value":"2690-442X"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,6]]}}}